Cargando…
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
INTRODUCTION: Experimental and clinical data show that the oral bisphosphonate clodronate (Bonefos(®)) can inhibit tumor-induced osteoclastic bone resorption. This randomized, double-blind, placebo-controlled, multicenter trial was designed to determine if the addition of oral clodronate to standard...
Autores principales: | Powles, Trevor, Paterson, Alexander, McCloskey, Eugene, Schein, Phil, Scheffler, Bobbi, Tidy, Alwynne, Ashley, Sue, Smith, Ian, Ottestad, Lars, Kanis, John |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557723/ https://www.ncbi.nlm.nih.gov/pubmed/16542503 http://dx.doi.org/10.1186/bcr1384 |
Ejemplares similares
-
Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
por: Powles, Trevor, et al.
Publicado: (2006) -
Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.
por: O'Rourke, N. P., et al.
Publicado: (1993) -
Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985) -
Potential Adverse Effect of Nonsteroidal Anti‐Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate
por: Zheng, Zhangan, et al.
Publicado: (2022) -
A high incidence of vertebral fracture in women with breast cancer
por: Kanis, J A, et al.
Publicado: (1999)